Euractiv (Advocacy Lab)
EU Perspectives
European Biotechnology Magazine
APM Market Access
EU PERSPECTIVES - Millions of medicine packs reach European pharmacies every day, on time, regardless of weather, shortages, or logistical complexity. The companies making that happen are largely invisible in EU policy discussions. The models they are paid by are 30 to 40 years out of date — and if nothing changes, you may one day walk into...
EU PERSPECTIVES - Expand, scrap, or keep it as it is? It depends on who you ask. A proposed extension of market protection for selected biotech medicines is dividing Brussels: industry is pushing for a wider scope, some MEPs want it removed entirely, while the European Commission is defending its current design. Read more
EURACTIV - The Biotech Act can help create a new confidence, proving that Europe wants to remain competitive in biotechnology, says Belgian life sciences leader Frédéric Druck. Read more
EUROPEAN BIOTECHNOLOGY MAGAZINE - The COVID-19 pandemic transformed RNA technologies into one of the most visible scientific breakthroughs of the decade. mRNA vaccines demonstrated unprecedented speed of development, large-scale manufacturing capability and global deployment, pushing RNA therapeutics into the public spotlight. But according to...
